V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
MedTech & Diagnostics

ResMed Executive Compensation (FY25)

RMD · Executive and director compensation, fiscal 2025 only
Data as of September 7, 2026Latest filing (8-K): November 20, 2025
268 figures on this page: 260 cited to the filing that reported them, 8 calculated from figures it prints. See the citations
Total compensation for Michael Farrell, Chairman of the Board and Chief Executive Officer, came to $14,674,543 in fiscal 2025. Meanwhile, the say-on-pay proposal drew 89.9% of votes cast for or against in favor at the meeting held November 19, 2025 for fiscal 2025. For fiscal 2025, the company reported a chief executive pay ratio of 187:1, against median employee compensation of $78,354, and the disclosed peer group includes Agilent Technologies, Inc., Align Technology, Inc., Amcor, Baxter International, Inc. and Bio-Rad Laboratories, Inc., among others. The fiscal 2025 disclosure covers 5 named executive officers.
Chief executive, fiscal 2025
◇
Michael Farrell
Latest say-on-pay support
=
November 19, 2025
Chief executive pay ratio
◇
To the median employee

Frequently asked questions

Answers drawn from the data on this page.
Who is ResMed's chief executive and what were they paid?
Total compensation for Michael Farrell, Chairman of the Board and Chief Executive Officer, came to $14,674,543 in fiscal 2025.
What was ResMed's say-on-pay result?
The say-on-pay proposal drew 89.9% of votes cast for or against in favor at the meeting held November 19, 2025 for fiscal 2025.
Which companies are in ResMed's peer group?
The disclosed peer group includes Agilent Technologies, Inc., Align Technology, Inc., Amcor, Baxter International, Inc. and Bio-Rad Laboratories, Inc., among others.
What is ResMed's chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 187:1, against median employee compensation of $78,354.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Michael Farrell
Chairman of the Board and Chief Executive Officer
◇—◇◇◇—◇◇
Justin Leong
Chief Product Officer
◇—◇—◇—◇◇
Bobby Ghoshal
Chief Commercial Officer, Residential Care Software
◇—◇—◇—◇◇
Brett Sandercock
Chief Financial Officer
◇—◇—◇—◇◇
Michael Rider
Global General Counsel and Secretary
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Bobby GhoshalPSU◇◇◇—◇—◇
Bobby GhoshalRSU◇——◇——◇
Bobby GhoshalPSU◇◇◇—◇—◇
Brett SandercockRSU◇——◇——◇
Brett SandercockPSU◇◇◇—◇—◇
Brett SandercockPSU◇◇◇—◇—◇
Justin LeongPSU◇◇◇—◇—◇
Justin LeongRSU◇——◇——◇
Justin LeongPSU◇◇◇—◇—◇
Michael FarrellPSU◇◇◇—◇—◇
Michael FarrellOPTION◇——◇—◇◇
Michael FarrellPSU◇◇◇—◇—◇
Michael FarrellRSU◇——◇——◇
Mike RiderRSU◇——◇——◇
Mike RiderPSU◇◇◇—◇—◇
Mike RiderPSU◇◇◇—◇—◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Bobby GhoshalOption◇—◇—
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Michael FarrellOption◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
Option◇—◇—
Brett SandercockOption◇—◇—
RSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Justin LeongRSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇—
Mike RiderRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Peter Farrell
◇◇◇——◇◇
Christopher DelOrefice
◇◇————◇
Ronald Taylor
Lead independent director
◇◇————◇
Carol Burt
◇◇————◇
Karen Drexler
◇◇————◇
Richard Sulpizio
◇◇————◇
Harjit Gill
◇◇————◇
John Hernandez
◇◇————◇
Jan De Witte
◇◇————◇
Desney Tan
◇◇————◇
Michael Farrell and Nicole Mowad-Nassar served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Lead independent director premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Agilent Technologies, Inc. A
  • Align Technology, Inc. ALGN
  • Amcor AMCR
  • Baxter International, Inc. BAX
  • Bio-Rad Laboratories, Inc. BIO
  • Brambles symbol not shown
  • Charles River Laboratories International, Inc. CRL
  • CSL Limited symbol not shown
  • Dentsply Sirona Inc. XRAY
  • Dexcom, Inc. DXCM
  • Edwards Lifesciences Corp. EW
  • Fisher & Paykel Healthcare Limited symbol not shown
  • Hologic Inc. HOLX
  • IDEXX Laboratories, Inc. IDXX
  • Illumina, Inc. ILMN
  • Intuitive Surgical, Inc. ISRG
  • James Hardie Industries PLC JHX
  • Mettler-Toledo International Inc. MTD
  • REA Group RPGRF
  • Revvity, Inc. RVTY
  • STERIS plc STE
  • Teleflex Incorporated TFX
  • Telstra symbol not shown
  • The Cooper Companies Inc. COO
  • Transurban symbol not shown
  • Waters Corporation WAT
  • Xero symbol not shown

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025November 19, 2025=◇◇◇
2024November 20, 2024=◇◇◇
2023November 16, 2023=◇◇◇
2022November 16, 2022=◇◇◇
2021November 18, 2021=◇◇◇
2020November 19, 2020=◇◇◇
2019November 21, 2019=◇◇◇
2018November 14, 2018=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when ResMed files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact ResMed disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where ResMed sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Enquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether ResMed's disclosed peer group is defensible, who names ResMed back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
268 figures on this page: 260 cited to the filing that reported them, 8 calculated from figures it prints.
260 cited to the filing
8 calculated from the filing

Documents cited

  1. 0001193125-25-289878
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0000943819-25-000079
    Chief Executive Officer Pay Ratio · Director Compensation · Director Compensation Table · Grants of Plan-Based Awards · and 3 more sections
  3. 0001193125-24-263501
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001193125-23-280656
    Item 5.07 Submission of Matters to a Vote of Security Holders
  5. 0001193125-22-287662
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001193125-21-334941
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001193125-20-299382
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001193125-19-298542
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001193125-18-328956
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “ResMed executive compensation, FY2025.” https://intel.velarion.ai/comp/RMD (accessed 2026).
Short form: data: Velarion
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about ResMed and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

MedTech & Diagnostics rankings

Chief executive pay — MedTech & DiagnosticsCEO pay ratio — MedTech & DiagnosticsSay-on-pay support — MedTech & Diagnostics

Peers ResMed discloses

The companies named in RMD's own disclosed peer group.

Agilent Technologies, Inc.Align Technology, Inc.Baxter International, Inc.Bio-Rad Laboratories, Inc.Charles River Laboratories International, Inc.Dentsply Sirona Inc.Dexcom, Inc.Edwards Lifesciences Corp.Hologic Inc.Illumina, Inc.Intuitive Surgical, Inc.Mettler-Toledo International Inc.Revvity, Inc.STERIS plcTeleflex IncorporatedThe Cooper Companies Inc.Waters Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  The Pay Desk · Methodology · Terms · Privacy